Larotrectinib is approved by NICE as an option for NTRK fusion-positive solid tumours Picture: iStock Essential facts Larotrectinib is one of a new breed of cancer drugs designed to target specific changes in the DNA of cancer cells, rather than where the disease is growing in the body. This means patients, including children, with various cancer types may benefit from its use. It is particularly useful for those patients at an advanced stage of cancer, when other options are limited or have been exhausted.
Less Intensive Treatment May Be Possible For Some Patients with HPV-Associated Head and Neck Cancer - SPOHNC: Support for People with Oral and Head and Neck Cancer
Changes in cancer treatment schedules may be possible, but proceed with caution
Future of cancer treatment: what will therapy look like in 2034?
Lynne Pearce, Page 12
How Immunotherapy Works To Treat Cancer
:max_bytes(150000):strip_icc()/VWH-MichelaButtignol-WhattoKnowAboutLungCancerClinicalTrials-Standard-5c4b6403b23c4a23b77a2e4e0b433af8.jpg)
Lung Cancer Clinical Trials: Purpose, Phases, and Risks
Cancer Patients Are at Higher Risk From Coronavirus Infection - WSJ
A biomarker has been identified in patients with head and neck cancer that will help to avoid unnecessary surgery - Diari digital de la URV
Lynne Pearce, Page 12
